Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cotadutide in CKD with Type 2 Diabetes
NCT04515849Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Primary completion
- Mar 2022
- Modality
- Peptides
- Countries
- 8
01
Overview
A Phase 2 trial of cotadutide in chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Aug 2020; status: completed.
02
Drugs
cotadutide
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04515849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04515849.